Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Henry Ford Health System
Study ID
NCT03850418
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Myeloid Malignancy

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • azacitidine — DRUG
    azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated

Study Details

Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD

Key Dates

Start date
Jul 1, 2019
Status verified
Feb 2026
Primary completion
Feb 20, 2028
Completion
Feb 20, 2028

Study Design

Enrollment
43 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: AZA
    azacitidine

Primary Outcome Measure

The rate of increase or stable donor chimerism [ Time Frame: one year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Henry ford hospitalDetroitMichigan48202
shatha farhan
313-916-5002

Find similar trials in Detroit, MI

By research site
Henry ford hospital· Detroit, MI

Related Studies